IBS study proves that CRISPR-Cas9 can be delivered directly into the eye of living animals to treat age-related macular degeneration efficiently and safely.
It is estimated that almost one in every ten people over 65 has some signs of age-related macular degeneration (AMD), and its prevalence is likely to increase as a consequence of the aging population. AMD is a form of blindness, common in Caucasians, which causes distorted vision and blind spots. Scientists at the Center for Genome Engineering, within the Institute for Basic Science (IBS) report the use of CRISPR-Cas9 in performing “gene surgery” in the layer of tissue that supports the retina of living mice. Published in Genome Research, this study combines basic research and mouse model applications.
The most common retinopathies causing blindness are ‘retinopathy of prematurity’ in children, ‘diabetic retinopathy’ and ‘AMD’ in older adults. In these diseases, abnormally high levels of the Vascular Endothelial Growth Factor (VEGF) are secreted. In AMD, VEGF causes the formation of new blood vessels in the eyes but also leads to leakages of blood and fluid into the eye, damaging an area at the center of the retina called macula.
Injections of anti-VEGF drugs are the most common treatment against AMD, but at least seven injections per year are required, because VEGF is continuously overexpressed by the cells of the diseased retinal pigment epithelium. Instead of such invasive treatments, IBS scientists believe that gene therapy with the third generation gene editing tool CRISPR-Cas9 could improve the situation. “The injections tackle the effects, but not the main cause of the problem. By editing the VEGF gene, we can achieve a longer-term cure,” explains KIM Jin-Soo, Director of the Center for Genome Engineering.
CRISPR-Cas9 can precisely cut and correct DNA at the desired site in the genome. The CRISPR-Cas9 system works by cutting DNA at a target site, in this case, inside the VEGF gene. Two year ago, IBS scientists proved that a pre-assembled version of CRISPR-Cas9, a.k.a, Cas9 ribonucleoprotein (RNP), can be delivered to cells and stem cells to modify target genes. The pre-assembled complex works rapidly and degrades before the body has time to build up an immune response against it. Despite these advantages and previous successes, the difficulty in delivering pre-assembled CRISPR-Cas9 has limited its use in therapeutic applications.
In this study, the research team successfully injected CRISPR-Cas9 into the eyes of a mice model with wet AMD and locally modified the VEGF gene. Initially they found that the delivery of the pre-assembled CRISPR-Cas9 complex is more efficient that the delivery of the same components in a plasmid form. Secondly, the complex disappeared after just 72 hours. Scientists assessed the whole genome of the animals and found the CRISPR-Cas9 complex modified only the VEGF gene and did not affect other genes. The progression of the eye disease was monitored by looking at choroidal neovascularization (CNV), the creation of new blood vessels between the retina and the sclera – a common problem of ‘wet’ macular degeneration – and researchers found the CNV area reduced by 58%. Moreover, a likely side effect, namely cone dysfunction, that takes only 3 days to show in these mice, did not occur a week after the treatment.
“We have developed a treatment to suppress CNV by inactivating the VEGF gene, one of the causes of AMD. We envision that, in the future, surgeons will be able to cut and paste disease-causing genetic elements in patients,” explains Kim Jin-Soo.
While CRISPR-Cas9 is conventionally used to correct mutations causing hereditary diseases or cancer, this study suggests a new therapy for non-hereditary degenerative disease.”We believe that this is a new therapeutic modality for the treatment of non-hereditary degenerative diseases,” points out Professor KIM Jeong Hun (Seoul National University), “We confirmed the effect on the animal models of the disease and now we wish to continue with preclinical trials.”
Receive an email update when we add a new AGE-RELATED MACULAR DEGENERATION article.
The Latest on: Age-related macular degeneration
via Google News
The Latest on: Age-related macular degeneration
- Trinity researchers announce major breakthrough in understanding dry age-related macular degenerationon September 26, 2019 at 9:15 am
Trinity College Dublin (TCD) scientists have announced a major breakthrough in the treatment of dry age-related macular degeneration (AMD). AMD can cause total blindness in sufferers, and there are ...
- Neutrophils homing into the retina trigger pathology in early age-related macular degenerationon September 20, 2019 at 3:36 am
Age-related macular degeneration (AMD) is an expanding problem as longevity increases worldwide. While inflammation clearly contributes to vision loss in AMD, the mechanism remains controversial. Here ...
- What's the Difference Between Dry and Wet Age-Related Macular Degeneration?on September 18, 2019 at 12:22 pm
The differences between dry age-related macular degeneration and wet age-related macular degeneration can be confusing, but they’re important to know. They could mean the difference between a ...
- What's the Difference Between Dry and Wet Age-Related Macular Degeneration?on September 14, 2019 at 5:00 pm
Learn what's different about the symptoms, diagnosis and treatment of dry versus wet macular degeneration. msn back to msn home lifestyle powered by Microsoft News web search Skip To Navigation Skip ...
- What’s the Difference Between Dry and Wet Age-Related Macular Degeneration?on September 12, 2019 at 1:00 pm
The differences between dry age-related macular degeneration and wet age-related macular degeneration can be confusing, but they’re important to know. They could mean the difference between a doctor ...
- Does This Macular Degeneration Study Deserve More Credit?on September 12, 2019 at 8:41 am
Adverum Biotechnologies Inc. (NASDAQ: ADVM) shares dropped sharply on Thursday after the firm announced data from its Optic Phase 1 clinical trial in wet age-related macular degeneration (wet AMD).
- FDA Accepts BLA for Abicipar Pegol for Neovascular Age-Related Macular Degenerationon September 10, 2019 at 2:18 pm
Results demonstrated abicipar pegol to be noninferior with similar efficacy after 6 or 8 injections compared with 13 ranibizumab injections at Week 52 The Food and Drug Administration (FDA) has ...
- A Patient's Guide to Macular Degenerationon September 10, 2019 at 9:10 am
Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, 11 million people in the U.S. have some type of age-related macular degeneration, ...
- BRIEF-Molecular Partners Says U.S. Marketing Application Accepted For Abicipar Pegol In Patients With Macular Degenerationon September 9, 2019 at 7:27 am
AGE-RELATED MACULAR DEGENERATION * MOLECULAR PARTNERS AG - FDA IS EXPECTED TO TAKE ACTION ON BLA MID-2020 * MOLECULAR PARTNERS AG - DECISION FROM EUROPEAN COMMISSION IS EXPECTED IN SECOND HALF OF 2020 ...
via Bing News